Caribou, MaxCyte enter CRISPR license agreement

By The Science Advisory Board staff writers

Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.

Under the agreement, Caribou gains rights to the use of MaxCyte's Flow Electroporation technology and ExPert platform for advancement of its CRISPR gene-edited allogenic T-cell therapy. Caribou will obtain nonexclusive clinical and commercial rights to the platform and in return MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to licensing fees.
Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking